Key facts
- EarlyDx’s last known valuation is $27.5M (Dec 2022).
- It has raised $14.0M; the latest was Later Stage VC in Jun 2025.
- Notable investors include National Institutes of Health, University of California, Alpha Edison, Device of Tomorrow Capital, Los Angeles — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for EarlyDx
- ·The full record, as it builds
Funding rounds
No funding rounds for EarlyDx are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About EarlyDx
Developer of a diagnostic and bioinformatics platform designed for early disease detection and health monitoring purposes. The company's platform integrates sequencing technology and computational methods to analyze genome-wide methylation profiles of cell-free DNA from a single blood sample, features an ultrasensitive library preparation technique, and provides cloud-based bioinformatics tools for data analysis, enabling healthcare providers and diagnostic companies to access affordable, non-invasive, and comprehensive solutions for cancer detection, therapy selection, and treatment monitoring.
- Sector
- Healthcare
- HQ
- Los Angeles, CA, United States
- Founded
- 2014
- Employees
- 8
- Website
- earlydx.com/
- Ownership
- Privately Held (backing)
EarlyDx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in EarlyDx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on EarlyDx in its N-PORT filings yet. We sweep new filings monthly.